The Coca-Cola Company 10-Qquarter ended 2026-10-02

Executive Summary

Coca-Cola sells beverage concentrates to bottling partners and finished drinks to retailers and distributors, earning revenue from both. Planned bottling divestitures continue its shift toward supplying brands and concentrates while partners handle more production and distribution. Q3 revenue grew 7.4%, supported primarily by volume rather than pricing, with international demand offsetting flat North American unit volumes. Operating margin reached 33.4% as pricing, currency and lower commodity pressure supported increased marketing investment. Broad demand growth supports the investment case, but the unresolved IRS dispute carries ≈$14B of potential exposure for earlier years alone.

What's Happening in the Business

• International demand led growth: Q3 unit case volume increased 5% worldwide, with gains across Europe, Middle East and Africa, Latin America, and Asia Pacific. Trademark Coca-Cola grew in every region; North American declines in water, sports drinks, coffee, tea and sparkling flavors offset its growth there.
• Affordability shaped regional results: Latin America benefited from volume, price/mix and favorable currency, while affordability initiatives weighed on Asia Pacific price/mix. Growth is therefore not translating equally into revenue across markets.
• Bottling ownership is shrinking: The planned African bottling sale to Coca-Cola HBC remains subject to approvals, with closing expected by year-end 2026. Singapore, Malaysia and Myanmar operations were classified as held for sale, with closing expected by mid-2027; these transactions would further shift operating responsibility to bottling partners.
• Brand investment increased: Q3 advertising expense rose 17% to $1.78B. BodyArmor remains a weaker spot: slower category growth, competition and disappointing performance prompted a prior-year trademark impairment and a more focused innovation and rollout plan.

Key Financial Highlights

• Concentrate operations: Q3 revenue of $8.20B, +9.3% Y/Y, outpaced finished-product operations and illustrates the importance of the partner-bottling model.
• Margin drivers: Gross margin reached 63.2%, from 61.5%, helped by pricing, favorable currency, stabilized commodity costs and the Nigerian operations sale. Bottling Investments also benefited from lower costs.
• Cash quality: The prior-year $6.07B fairlife payment explains much of the cash-flow rebound rather than recurring operating improvement. Receivables factoring remained significant, with $10.6B sold during 9M and proceeds classified as operating cash flow.
• Capital allocation: Debt declined 8.5% from year-end to $41.6B. Dividends consumed $6.84B, partly reflecting payment timing; $900M of treasury-share purchases left shares outstanding unchanged, consistent with management’s dilution-offset objective rather than share-count reduction.

Risk Assessment

• IRS litigation: Coca-Cola’s appeal remains unresolved; an adverse outcome could jeopardize its $6.0B payment recorded as an asset and trigger further liabilities, including ≈$14B estimated for 2010–2025 plus $1.4B of estimated additional 9M 2026 exposure.
• BodyArmor valuation: The trademark’s $2.44B carrying value approximates fair value after the prior-year impairment, leaving little valuation cushion if sales disappoint or discount rates rise.
• North American demand: Flat unit volume and weakness across several beverage categories make growth dependent on Trademark Coca-Cola and pricing, exposing results if consumer demand weakens further.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: the company's 10-Ks on SEC.

What to Watch

• North American demand recovery: Trademark Coca-Cola is offsetting declines elsewhere; broader category stabilization would support growth, while continued weakness would leave the region reliant on its flagship brand.
• BodyArmor’s focused rollout: Later filings should show whether narrower innovation priorities improve performance; further weakness or another trademark impairment would undermine the recovery case.
• Bottling divestitures: Completion on management’s stated timelines would advance the partner-led model; delays or further sale-related write-downs would weaken the expected benefits.
• IRS appeal: The hearing occurred on 6/25/2026. A favorable ruling could protect recovery of the payment, while an adverse ruling could materially change cash requirements and future tax expense.